Dr Lopes speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about results from a trial that show front line pembrolizumab surpassed chemotherapy for lung cancer patients whose tumours had PD-L1 expression and no EGFR/ALK rearrangements.

For more on these results, watch Dr Lopes present the data in a press conference here and read our news coverage here.
[ Ссылка ]
[ Ссылка ]

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php

свернуть